Jerome D. Jabbour

This profile gathers the share dealings of Jerome D. Jabbour in Matinas BioPharma Holdings, Inc., where the filings describe the role as chief executive. In total, 7 filings cover trades dated from 12 June 2019 to 19 June 2021.

On the market, this insider has only ever bought: 3 purchases, €24k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.

A typical purchase (the median) is worth €8,835. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 24 June 2021 with a transaction in Matinas BioPharma Holdings, Inc. The clock since the last published purchase (18 March 2020) now reads 2,410 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.